Measles virus (Edmonston strain)-mediated oncolytic lysis (MV (if referring to measles virus); Oncolytic MV)

Oncolytic measles virus therapy uses engineered or attenuated measles virus strains such as MV-Edmonston to selectively infect, replicate within, and destroy cancer cells. This process involves fusion of infected cells into non-viable multinucleated syncytia (oncolysis), viral propagation within the tumor, and activation of host anti-tumor immune responses. Engineered variants (e.g., MV-NIS) allow for improved tumor targeting and enable imaging or radiotherapeutic approaches. Tumor selectivity is partly mediated by high expression of the MV receptor *Nectin-4* in certain cancers. Key therapeutic challenges include pre-existing measles immunity and safety, which are addressed by gene engineering, use of cell carriers, and combination with immunosuppressive drugs. This "target" is not a traditional molecular entity but a therapeutic viral platform designed for anti-cancer activity[2][1][3].

Other names

oncolytic measles virusMV-EdmMV-NIS (a genetically modified variant)Edmonston strain measles virus

Preferential infection and replication in cancer cells, leading to direct lysis (oncolysis) Induction of immune-mediated anti-tumor effects by release of tumor antigens and activation of T cell responses Formation of multinucleated *syncytia* from fusion of infected cells, resulting in cell death